Dabrafenib in BRAF V600E–Mutant Advanced Non-Small Cell Lung Cancer: an Open-label, Single arm, Multicenter, Phase 2 Trial

BACKGROUND: Activating BRAF V600E mutations are found in approximately 1–2% of adenocarcinomas of the lung offering an opportunity to test targeted therapy for this disease. Dabrafenib is an oral selective inhibitor of the BRAF kinase. The aim of this study was to assess the clinical activity of dab...

全面介紹

Na minha lista:
書目詳細資料
發表在:Lancet Oncol
Main Authors: Planchard, David, Kim, Tae Min, Mazieres, Julien, Quoix, Elisabeth, Riely, Gregory, Barlesi, Fabrice, Souquet, Pierre-John, Smit, Egbert F., Groen, Harry J. M., Kelly, Ronan J., Cho, B. C., Socinski, Mark A., Pandite, Lini, Nase, Christine, Ma, Bo, D’Amelio, Anthony, Mookerjee, Bijoyesh, Curtis, C. Martin, Johnson, Bruce E.
格式: Artigo
語言:Inglês
出版: 2016
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006181/
https://ncbi.nlm.nih.gov/pubmed/27080216
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)00077-2
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍